key: cord-0761705-rbooi2ta
authors: Qi, Huan; Ma, Mingliang; Lai, Danyun; Li, Yang; Zhang, Fucheng; Tao, Sheng-ce
title: Assessment and comparison of recombinant proteins from different sources for the detection of SARS-CoV-2 infection by using protein microarray
date: 2020-12-21
journal: Acta Biochim Biophys Sin (Shanghai)
DOI: 10.1093/abbs/gmaa152
sha: 72800bdb4930d5148492bc8ca27be82c66962b35
doc_id: 761705
cord_uid: rbooi2ta

nan

IgM. The other secondary antibody DyLight TM 649 affinipure donkey anti-human IgM (Jackson ImmunoResearch) interacts with the human IgM, not human IgG. No interference between human IgG and IgM exists. These results demonstrated that both secondary antibodies can be used to measure the human IgG and IgM respectively. Secondly, each spot for investigation of IgG and IgM in the serum has good morphology and uniform fluorescence intensity (FI). Thirdly, many IgG and IgM against N protein, S protein, and related domains exist in the standard serum. No or few antibodies against ACE2, E protein, 3C-like proteinase, and papain-like proteinase exist. These results are the same as our earlier results [10] . In a word, the protein microarray with high quality was fabricated.

According to the protocol described previously [10] , a set of 36 COVID-19 serum and 36 control serum are profiled by protein microarray. There is no significant difference between the two groups with regard to age and gender. One section of the protein microarray, with the protein concentration of 0.125 mg/ml, demonstrated the best performance, such as enough sensitivity, no interference between the two adjacent spots, and no smearing. As a result, the FI of this section for every serum is used to estimate the diagnosis value of each protein. Meanwhile, the proteins, including ACE2, E protein, 3C-like proteinases, and papain-like proteinase, were not analyzed further for low FI.

According to the FI of immobilized human IgG/IgM on the protein microarray, all the FI values of other proteins in protein microarray for investigating the IgG/IgM in the serum are normalized. For the SARS-CoV-2 specific IgG in serum, as shown in Fig. 2A , all the S1 domains, S2-related domains, RBDs, and N proteins (expressed in either mammalian cells or baculovirus-insect cells) told the COVID-19 patients from the healthy persons. Furthermore, analysis by receiver operating characteristic (ROC) curve for each protein was carried out. The area under curve (AUC) for each protein, except protein 3#, was 1.00, which demonstrated that these proteins could tell the COVID-19 patients from the healthy ones thoroughly. For the SARS-CoV-2 specific IgM in serum, as shown in Fig. 2B , all S1 domains, S2-related domains, RBDs, and N proteins also told the COVID-19 patients from the healthy persons. Similarly, ROC analysis for each protein was also performed. The AUC of proteins 7#, 10#, 11#, 12#, 13#, or 16# was 1.00 (Fig. 2B, bottom) . The AUC of protein 29# is 0.94206, which is the smallest one. However, its diagnosis performance is still good.

Compared with their performances in profiling SARS-CoV-2 specific IgM in serum, some proteins, such as 8#, 9#, 15# or 17# were better in profiling SARS-CoV-2 specific IgG in serum. This was resulted from the serum samples. The serum might be with low titer IgM for antigens of SARS-CoV-2, because they were collected from COVID-19 patients at the convalescent stage.

The last but not least, the normalized FI of some antigens demonstrated significant difference, even from the same supplier with different formulation, liquid or lyophilized. All these results suggest that differences, such as the glycan modification, exist in the same antigens.

Taken together, we estimated the diagnosis value of antigens from several suppliers by protein microarray. All the S1 domains, S2-related domains, RBDs, and N proteins, produced from the mammalian or insect cells, can be used to develop the diagnosis method for COVID-19, of which all the S proteins with full length, and a smaller substitute S1 from CactusBiosystem with liquid format, even the smallest substitute RBD from Sino Biological demonstrated 100% sensitivity and 100% specificity (labeled as the red star in the bottom of Fig. 2B) . These might provide the guidelines for preparation and choice of antigens in developing diagnosis methods for COVID-19.

An interactive web-based dashboard to track COVID-19 in real time

Laboratory diagnosis of coronavirus disease-2019 (COVID-19)

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein

A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019

Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity

SARS-CoV-2 infection serology: a useful tool to overcome lockdown?

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

Establishment of a new human pneumococcal standard reference serum

We thank Zhicai Wu in AbClonal, Inc. (Wuhan, China) for providing the antigens related to SARS-CoV-2.

This work was partially supported by the grants from the National Key Research and Development Program of China (No. 2016YFA0500600) and Open Foundation of Key Laboratory of Systems Biomedicine (Nos. KLSB2017QN-01 and KLSB2020QN-05).

The authors declare there is no any confilct of interests.